ArticleBMC pregnancy and childbirth2025
Expression and clinical significance of miR-377-3p and cyclin G2 in preeclampsia patients.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesNumerous studies have demonstrated that differentially expressed microRNA (miRNA) play a crucial role in the pathophysiology of preeclampsia (PE). These miRNA are central to ongoing investigations into the pathogenesis of PE. This study aims to investigate the relationship between changes in miR-377-3p and cell cyclin G2 (CCNG2) expression and the clinical features of PE, as well as to further analyze the effect of miR-377-3p on CCNG2.
methodsA total of 120 pregnant subjects were recruited, consisting of 70 PE cases and 50 healthy pregnancies. The expression levels of miR-377-3p and CCNG2 mRNA were detected through RT-qPCR, while the protein expression of CCNG2 was examined via Western blot. The Pearson test was employed to analyze the relationship between miR-377-3p and CCNG2 mRNA expression and clinical parameters related to PE. The effect of miR-377-3p on CCNG2 was verified using a dual-luciferase reporter assay.
resultsCompared with normal controls, miR-377-3p was significantly down-regulated in PE plasma and placental tissues, while CCNG2 was up-regulated (P < 0.05). The abnormal expression of both miR-377-3p and CCNG2 was associated with the severity of PE. The expression of miR-377-3p and CCNG2 mRNA in the plasma and placenta of PE patients was significantly correlated with systolic blood pressure (SBP), diastolic blood pressure (DBP), and neonatal birth weight (P < 0.05). Moreover, miR-377-3p and CCNG2 were consistently expressed in plasma and placental tissues (r = 0.521, P < 0.01; r = 0.247, P = 0.039), and the expression of the two was negatively correlated (plasma: r = - 0.475, P < 0.05; placental: r = - 0.497, P < 0.05). The dual-luciferase reporter assay confirmed that miR-377-3p negatively regulated CCNG2 expression in HTR-8/SVneo cells.
conclusionThe low expression of miR-377-3p, alongside the high expression of CCNG2 in the peripheral plasma and placental tissues of PE patients, may be linked to the onset of the condition. These findings suggest that miR-377-3p may contribute to the development of PE by regulating the expression of CCNG2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.